Loading...
XNASIRD
Market cap38mUSD
Jan 10, Last price  
1.42USD
1D
-2.07%
1Q
16.39%
Jan 2017
0.07%
Name

Ocuphire Pharma Inc

Chart & Performance

D1W1MN
XNAS:IRD chart
P/E
—
P/S
2.02
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
99.35%
Rev. gr., 5y
%
Revenues
19m
-52.20%
190,61000000000000000589,00039,850,00019,049,000
Net income
-10m
L
-6,349,540-6,486,003-4,304,005-4,912,148-6,387,428-11,344,950-6,226,670-9,499,424-18,521,601-14,384,556-9,307,345-25,294,503-14,368,530-7,510,000-31,476,000-56,534,00017,888,000-9,986,000
CFO
-1m
L
-4,131,450-4,131,450-3,394,8390-5,146,845-6,986,5982,011-15,530,306-7,984,856-11,041,211-17,351,950-13,227,101-15,420,055-18,938,638-3,593,000-6,797,000-19,370,00014,314,000-1,112,000
Earnings
Mar 06, 2025

Profile

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
URL
https://www.ocuphire.com/
IPO date
Nov 30, 2004
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
19,049
-52.20%
39,850
6,665.70%
Cost of revenue
29,612
21,628
Unusual Expense (Income)
NOPBT
(10,563)
18,222
NOPBT Margin
45.73%
Operating Taxes
12
315
Tax Rate
1.73%
NOPAT
(10,575)
17,907
Net income
(9,986)
-155.83%
17,888
-131.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,227
4,428
BB yield
-14.20%
-6.09%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
433
Net debt
(50,516)
(42,683)
Cash flow
Cash from operating activities
(1,112)
14,314
CAPEX
Cash from investing activities
Cash from financing activities
8,979
3,786
FCF
(7,019)
14,361
Balance
Cash
50,516
42,683
Long term investments
Excess cash
49,564
40,690
Stockholders' equity
(81,464)
(71,478)
Invested Capital
131,370
116,766
ROIC
15.65%
ROCE
39.68%
EV
Common stock shares outstanding
21,590
20,597
Price
3.01
-14.73%
3.53
-5.36%
Market cap
64,985
-10.62%
72,708
31.24%
EV
14,469
30,025
EBITDA
(10,557)
18,226
EV/EBITDA
1.65
Interest
9
Interest/NOPBT
0.05%